TECHNOLOGY:
Saans NIV: A low cost, fully automated, multimode, skill independent non invasive ventilation system.
AFFILIATION:
InnAccel Technologies Pvt. Ltd., Bangalore, Karnataka, India
TECHNOLOGY SUMMARY
Area:
Technologies for improved delivery of supplemental oxygen
Tech Brief: The Saans Pro NIV device is an intelligent, AI-powered, Non-Invasive Ventilation a system that expands access to high-quality NIV (CPAP, BiPAP, HFNC, PAP, PAP) therapy to non-ICU settings, including home care and transport. This is a first in world device to take ICU level NIV to outside of ICU.
SHOWCASE SUMMARY
Org Type:
Mid-stage Startup (A or B)
FIGURES OF MERIT
Value Proposition: This technology will expand access to non-invasive oxygen therapy, for both Covid and non-Covid patients, by making this treatment available outside the ICU, and in the home setting. Our technology can therefore address the shortage of ICU beds and respiratory therapists, by moving treatment for less severe cases outside the ICU setting or to home- improving clinical outcomes, patient well-being, and caregiver safety. For commercial partners, this technology offers an important addition to their respiratory care portfolio, and/or to their home care portfolio. Given the large and growing incidence of respiratory disease requiring oxygen therapy, there is a significant opportunity in making oxygen therapy available in non-ICU settings and at home, thereby greatly expanding the addressable market for oxygen therapy. A partnership with InnAccel would also provide the partner access to other respiratory care and other products in our portfolio. For investors, this technology represents a high-value innovation with low technology risk, as the base version of this technology, has been successfully deployed commercially in Covid wards across India, and the market opportunity is huge, given the large and growing incidence of respiratory disease globally, and our technology is uniquely positioned to tap this opportunity.